# Rejuvenation Technologies Inc.

> Rejuvenation Technologies is a Stanford-spun biotech developing modified-mRNA therapeutics that temporarily switch on telomerase to lengthen telomeres and reverse cellular aging in specific tissues. Its lead programs target fibrotic and age-related diseases such as pulmonary fibrosis, chronic liver disease and bone-marrow failure, delivered by proprietary tissue-targeted lipid nanoparticles. Backed by Khosla Ventures and Y Combinator, the company holds 50+ patents and is advancing toward Phase I clinical readouts.

- **Founded:** 2016
- **Headquarters:** Mountain View, California, United States
- **Founders:** John Ramunas (Co-Founder & CEO), Glenn Markov (Co-Founder & COO), Helen Blau (Scientific Co-Founder)
- **Team size:** ~20
- **Products:** TERT mRNA telomere-extension platform, Tissue-targeted lipid nanoparticles (LNP), TeloHep (chronic liver disease), TeloAT2 (pulmonary fibrosis), TeloHSC (hematologic conditions)
- **Notable:** Reversed 5+ years of telomere shortening in a single day in preclinical work, 50+ granted patents across 7 patent families, FDA INTERACT clearance obtained for its lead approach

## Products & services

- **TERT mRNA telomere-extension platform** — Modified mRNA encoding telomerase (TERT) that transiently activates the enzyme to lengthen telomeres in target cells, then clears - avoiding permanent telomerase expression and its cancer risk.
- **Tissue-targeted lipid nanoparticles (LNP)** — Proprietary LNP delivery system that routes the telomerase mRNA to specific organs while minimizing off-target effects.
- **TeloHep (chronic liver disease)** — Telomere-extension program aimed at compensated cirrhosis and other chronic liver conditions.
- **TeloAT2 (pulmonary fibrosis)** — Program targeting idiopathic pulmonary fibrosis by rejuvenating lung epithelial cells.
- **TeloHSC (hematologic conditions)** — Program aimed at bone-marrow failure and blood-forming stem cell disorders.

## Achievements

- Reversed 5+ years of telomere shortening in a single day in preclinical work
- 50+ granted patents across 7 patent families
- FDA INTERACT clearance obtained for its lead approach
- Preclinical efficacy demonstrated across multiple organ systems
- $15M+ raised across dilutive and non-dilutive funding
- Backed by Khosla Ventures and Y Combinator

## Latest updates

- **2023-09** — Exited stealth with a $10.6M seed round led by Khosla Ventures to develop age-reversing mRNA therapeutics.
- **2025** — Raising a seed extension and advancing programs toward IND/clinical trials, with a Phase I readout targeted for Q3 2027.

## Links

- Website: https://rejuvenationtech.com
- LinkedIn: http://www.linkedin.com/company/rejuvenation-tech

---

Profile page: https://yespress.io/rejuvenation-technologies-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-03